Lab Bulletin your partner in science

AMSBIO has announced a new range of highly efficient knockdown cell lines covering the Base Excision DNA Repair pathway.
 
The new range of 20 DNA Repair Knockdown cell lines was developed to enable scientists to study the molecular etiology of tumour genomic instability and to exploit it in oncology research. The AMSBIO DNA Repair Knockdown cell lines are based upon target-specific LN428 glioblastoma shRNA lentivirus transduced cells that are rigorously qualified and mycoplasma free.

DNA repair pathways maintain the integrity of the genome, reducing the onset of cancer, disease and aging phenotypes. The requirement for DNA repair and genome maintenance in response to radiation and genotoxic chemotherapeutics implicates DNA repair proteins as prime targets for improving response to currently available anti-cancer regimens.  AMSBIO's DNA repair knockdown cell lines provide essential tools to address these needs.

All AMSBIO DNA Repair Knockdown Cell Line products are evaluated by RT-PCR and Western Blots in addition functional assays are performed were feasible. The knockdown efficiency of the new DNA Repair Knockdown Cell Lines on target genes, as measured by RT-PCR, is 63-98%.

For further information on DNA Repair Knockdown Cell lines please click here or contact AMSBIO on +44-1235-828200 / email info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading international provider of unique & innovative products & custom services for life sciences research. The amsbio range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification & stem cell biology.

blog comments powered by Disqus